225 related articles for article (PubMed ID: 25845317)
1. [Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum].
Doma V; Gulya E
Orv Hetil; 2015 Apr; 156(15):583-91. PubMed ID: 25845317
[TBL] [Abstract][Full Text] [Related]
2. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Miller DM; Flaherty KT; Tsao H
Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology of melanoma.
Swick JM; Maize JC
J Am Acad Dermatol; 2012 Nov; 67(5):1049-54. PubMed ID: 22459362
[TBL] [Abstract][Full Text] [Related]
4. Melanoma treatment's changing landscape.
Jenks S
J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
[No Abstract] [Full Text] [Related]
5. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
Levine O; Devji T; Xie F
Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
[No Abstract] [Full Text] [Related]
6. [Prognostic and predictive markers of malignant melanoma].
Rásó E; Barbai T; Gyõrffy B; Tímár J
Magy Onkol; 2013 Jun; 57(2):79-83. PubMed ID: 23795352
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
8. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
[TBL] [Abstract][Full Text] [Related]
9. Recent discoveries in the genetics of melanoma and their therapeutic implications.
Marquette A; Bagot M; Bensussan A; Dumaz N
Arch Immunol Ther Exp (Warsz); 2007; 55(6):363-72. PubMed ID: 18060370
[TBL] [Abstract][Full Text] [Related]
10. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P
Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579
[TBL] [Abstract][Full Text] [Related]
11. Advances in the treatment of late stage melanoma.
Walkington LA; Lorigan P; Danson SJ
BMJ; 2013 Mar; 346():f1265. PubMed ID: 23460638
[No Abstract] [Full Text] [Related]
12. [Therapeutic approaches in Melanoma - a paradigm for personalized medicine].
Dummer R; Goldinger S; Rinderknecht J; Eggmann N; Felderer L; Braun R; French LE
Praxis (Bern 1994); 2012 Jul; 101(15):955-9. PubMed ID: 22811327
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in malignant melanoma.
Atkinson V
Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
[TBL] [Abstract][Full Text] [Related]
14. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Girotti MR; Saturno G; Lorigan P; Marais R
Mol Oncol; 2014 Sep; 8(6):1140-58. PubMed ID: 25178978
[TBL] [Abstract][Full Text] [Related]
15. Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies.
Newcomer K; Robbins KJ; Perone J; Hinojosa FL; Chen D; Jones S; Kaufman CK; Weiser R; Fields RC; Tyler DS
Curr Probl Surg; 2022 Jan; 59(1):101030. PubMed ID: 35033317
[No Abstract] [Full Text] [Related]
16. [Paradigmatic shift in oncology: individualized melanoma treatment].
Hansson J; Djureen-Mårtenson E; Edvinsson F; Falkenius J; Friesland S; Masucci G; Månsson-Brahme E; Ragnarsson-Olding B; Sjödin H; Wolodarski M; Frohm-Nilsson M; Lapins J
Lakartidningen; 2011 May 18-24; 108(20):1092-3. PubMed ID: 21815339
[No Abstract] [Full Text] [Related]
17. The role of targeted therapy for melanoma in the immunotherapy era.
Sullivan RJ
Semin Cutan Med Surg; 2018 Jun; 37(2):112-119. PubMed ID: 30040088
[TBL] [Abstract][Full Text] [Related]
18. SEOM clinical guideline for the management of cutaneous melanoma (2020).
Majem M; Manzano JL; Marquez-Rodas I; Mujika K; Muñoz-Couselo E; Pérez-Ruiz E; de la Cruz-Merino L; Espinosa E; Gonzalez-Cao M; Berrocal A
Clin Transl Oncol; 2021 May; 23(5):948-960. PubMed ID: 33651321
[TBL] [Abstract][Full Text] [Related]
19. Molecular testing in malignant melanoma.
Grossmann AH; Grossmann KF; Wallander ML
Diagn Cytopathol; 2012 Jun; 40(6):503-10. PubMed ID: 22619125
[TBL] [Abstract][Full Text] [Related]
20. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
